[{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anti-Corona (COVID-19) IgG product","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Kamada \/ Not Applicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Anti-SARS-CoV-2 polyclonal immunoglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Kedrion Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Kamada \/ Kedrion Biopharma"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Rabies Immune Globulin [Human]","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Alpha1-Proteinase Inhibitor (Human)","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kamada","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Solution For Infusion","sponsorNew":"Kamada \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Takeda"},{"orgOrder":0,"company":"Kamada","sponsor":"Israeli Health Authorities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"COVID-19 IgG Therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Israeli Health Authorities","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Israeli Health Authorities"},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Human Alpha 1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kamada","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Inhaler","sponsorNew":"Kamada \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ Takeda"},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Plasma-derived hyperimmune globulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Not Applicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Saol therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Cytomegalovirus Immune Globulin [Human]","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kamada","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14999999999999999,"dosageForm":"Intravenous","sponsorNew":"Kamada \/ Kamada Ltd.","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Kamada Ltd."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Alpha1-Proteinase Inhibitor","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Not Applicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Varicella Zoster Immune Globulin (Human)","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kamada","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Human Alpha1-proteinase","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ Not Applicable"},{"orgOrder":0,"company":"Kamada","sponsor":"AcuCort","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Dexamethasone","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film","sponsorNew":"Kamada \/ Kamada","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Kamada"},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Cytomegalovirus Immune Globulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Not Applicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cytomegalovirus Human Immune Globulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Not Applicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Not Applicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Human Rabies Immune Globulin","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Rabies Immune Globulin (Human)","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kamada","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ Kamada"}]

Find Clinical Drug Pipeline Developments & Deals by Kamada

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The commercial agreement includes potential expansion of Kedrion's distribution of Kedrab, a Human Rabies Immune Globulin, in additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products...

Brand Name : Kedrab

Molecule Type : Large molecule

Upfront Cash : Undisclosed

December 07, 2023

Lead Product(s) : Rabies Immune Globulin (Human)

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Recipient : Kedrion

Deal Size : Undisclosed

Deal Type : Agreement

blank

02

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The agreement aims for the distribution of Kedrab (Rabies Immune Globulin [Human]), which is indicated for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid, in the U...

Brand Name : Kedrab

Molecule Type : Large molecule

Upfront Cash : Undisclosed

July 12, 2023

Lead Product(s) : Human Rabies Immune Globulin

Therapeutic Area : Immunology

Highest Development Status : Approved

Sponsor : Kedrion

Deal Size : Undisclosed

Deal Type : Agreement

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Glassia is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1, also known as alpha1-antitrypsin (AAT) deficien...

Brand Name : Glassia

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 16, 2023

Lead Product(s) : Human Alpha1-Proteinase Inhibitor

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Cytogam (Human cytomegalovirus) Immuno Globulin Intravenous is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart.

Brand Name : Cytogam

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 03, 2023

Lead Product(s) : Cytomegalovirus Human Immune Globulin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Cytogam (Human cytomegalovirus) Immuno Globulin Intravenous is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart.

Brand Name : Cytogam

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 04, 2023

Lead Product(s) : Human Cytomegalovirus Immune Globulin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Under the terms of the agreement, Kamada is responsible for the commercialization of Zeqmelit™ (dexamethasone) in Israel and has the exclusive right to marketing, sales, and distribution of the drug in this market.

Brand Name : Zeqmelit

Molecule Type : Small molecule

Upfront Cash : Undisclosed

November 23, 2022

Lead Product(s) : Dexamethasone

Therapeutic Area : Immunology

Highest Development Status : Approved

Recipient : AcuCort

Deal Size : Undisclosed

Deal Type : Agreement

blank

07

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF.

Brand Name : Glassia

Molecule Type : Large molecule

Upfront Cash : Not Applicable

November 07, 2022

Lead Product(s) : Human Alpha1-proteinase

Therapeutic Area : Genetic Disease

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : VARIZIG (Varicella Zoster Immune Globulin), one of four acquired FDA-approved commercial products by Kamada, contains antibodies specific for the Varicella zoster virus, and is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-ris...

Brand Name : Varizig

Molecule Type : Large molecule

Upfront Cash : Undisclosed

July 06, 2022

Lead Product(s) : Varicella Zoster Immune Globulin (Human)

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Undisclosed

Deal Size : $11.4 million

Deal Type : Agreement

blank

09

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : GLASSIA, is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1 -PI, also known as alpha1 -antitrypsin deficien...

Brand Name : Glassia

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 17, 2022

Lead Product(s) : Alpha1-Proteinase Inhibitor

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.

Brand Name : Cytogam

Molecule Type : Large molecule

Upfront Cash : $95.0 million

November 22, 2021

Lead Product(s) : Cytomegalovirus Immune Globulin [Human],Ganciclovir

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Recipient : Saol therapeutics

Deal Size : $145.0 million

Deal Type : Acquisition

blank